Asia On The Move: Personnel News From Shanghai Pharma, Daiichi Sankyo, Merck Serono, Mindray, GSK
This article was originally published in PharmAsia News
Shanghai Pharma has a new CEO after a large shakeup, and GSK appoints an interim head of discovery in China after Nature Medicine fallout. Mindray returns to co-CEO model, and personnel changes occur at Astellas, Merck Serono, Daiichi Sankyo and RDPAC.
You may also be interested in...
Junshi’s oral antiviral shows signs of effectiveness in treating patients with mild COVID-19 symptoms but more data are needed, caution researchers.
2021 saw a record number of novel drug launches and the size of the pipeline topped 20,000 candidates for the first time, new analysis shows, while China came of age as a pharma player.
Important changes are coming to China's Drug Administration Law as the government aims to address through several revisions a number of key issues since the law’s original enactment in 2019.